Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

The Phillippines (1)

United Arab Emirates (1)

19.12.2017
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH

STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and …

Read more

15.11.2017
STADA Health Report 2017: Young adults lack health education
STADA Health Report 2017: Young adults lack health education

STADA Health Report 2017: Young adults lack health education

Read more

09.11.2017
STADA shows good business development in the third quarter of 2017 and the first nine months
STADA shows good business development in the third quarter of 2017 and the first nine months

STADA shows good business development in the third quarter of 2017 and the first nine months

Read more

27.10.2017
Luc Slegers to hand over responsibility for STADA Europe after 26 years
Luc Slegers to hand over responsibility for STADA Europe after 26 years

Luc Slegers to hand over responsibility for STADA Europe after 26 years

Read more

17.10.2017
Frank Staud assumes overall responsibility for the STADA brand and communications
Frank Staud assumes overall responsibility for the STADA brand and communications

Frank Staud assumes overall responsibility for the STADA brand and communications

Read more

28.09.2017
Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG
Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG

Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG

Read more

27.09.2017
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Read more

30.08.2017
STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed
STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed

STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed

Read more

25.08.2017
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Read more

25.08.2017
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Read more

25.08.2017
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Read more

24.08.2017
Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding AG
Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding AG

Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding …

Read more

18.08.2017
STADA takeover offer by Bain Capital and Cinven successful
STADA takeover offer by Bain Capital and Cinven successful

STADA takeover offer by Bain Capital and Cinven successful

Read more

18.08.2017
Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached
Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached

Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached

Read more

03.08.2017
STADA shows good operational development in first six months of 2017
STADA shows good operational development in first six months of 2017

STADA shows good operational development in first six months of 2017

Read more

25.07.2017
Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven
Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven

Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven

Read more

19.07.2017
Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG
Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG

Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG

Read more

10.07.2017
STADA supports renewed improved takeover offer announced by Bain Capital and Cinven
STADA supports renewed improved takeover offer announced by Bain Capital and Cinven

STADA supports renewed improved takeover offer announced by Bain Capital and Cinven

Read more

10.07.2017
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover of…

Read more

04.07.2017
STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions
STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions

STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions

Read more

04.07.2017
Changes in the Executive Board of STADA Arzneimittel AG
Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Read more

04.07.2017
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the…

Read more

26.06.2017
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven fails – STADA to continue pursuing successful growth strategy
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven fails – STADA to continue pursuing successful growth strategy

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven fails – STADA to continue pursuing successful growth strat…

Read more

26.06.2017
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

Read more

07.06.2017
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017

STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5…

Read more

06.06.2017
Holger Pohlen is new Director of Media Relations at STADA Arzneimittel AG
Holger Pohlen is new Director of Media Relations at STADA Arzneimittel AG

Holger Pohlen is new Director of Media Relations at STADA Arzneimittel AG

Read more

11.05.2017
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Capital and Cinven
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Capital and Cinven

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Ca…

Read more

11.05.2017
STADA: Very good start in first quarter 2017
STADA: Very good start in first quarter 2017

STADA: Very good start in first quarter 2017

Read more

11.05.2017
Interview with Dr. Matthias Wiedenfels on the occasion of the publication of the figures for the first quarter of 2017
Interview with Dr. Matthias Wiedenfels on the occasion of the publication of the figures for the first quarter of 2017

Interview with Dr. Matthias Wiedenfels on the occasion of the publication of the figures for the first quarter of 2017

Read more

27.04.2017
STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven
STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven

STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven

Read more

24.04.2017
Dr. Ralph Grobecker to become Managing Director of STADA’s OTC segment
Dr. Ralph Grobecker to become Managing Director of STADA’s OTC segment

Dr. Ralph Grobecker to become Managing Director of STADA’s OTC segment

Read more

10.04.2017
To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven
To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven

To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven

Read more

10.04.2017
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

Read more

29.03.2017
STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised
STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised

STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised

Read more

21.03.2017
STADA postpones press and analyst conference on full year figures 2016  to March 29, 2017
STADA postpones press and analyst conference on full year figures 2016 to March 29, 2017

STADA postpones press and analyst conference on full year figures 2016
to March 29, 2017

Read more

17.03.2017
STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”
STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”

STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”

Read more

17.03.2017
STADA raises medium-term growth targets
STADA raises medium-term growth targets

STADA raises medium-term growth targets

Read more

16.03.2017
STADA: Statement on media reports
STADA: Statement on media reports

STADA: Statement on media reports

Read more

16.02.2017
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

Read more

16.02.2017
STADA Supervisory Board establishes Ad Hoc Committee
STADA Supervisory Board establishes Ad Hoc Committee

STADA Supervisory Board establishes Ad Hoc Committee

Read more

12.02.2017
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

Read more

23.01.2017
Changes in the Executive Board of STADA Arzneimittel AG
Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Read more